Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066333 · ClinicalTrials.gov registry record · Phase 2
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
A Phase 2 study of Adrenocortical Carcinoma and ACC, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT06066333 is a Phase 2 study of Adrenocortical Carcinoma and ACC that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 362-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06066333, a Phase 2 study of Adrenocortical Carcinoma and ACC, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Ablative Radiotherapy
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2026-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066333
The ClinicalTrials.gov registry entry for NCT06066333 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 362-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06066333 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06066333 about?
NCT06066333 is a clinical study titled "Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma". The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
What is the current status of trial NCT06066333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-09-27. Estimated completion is 2026-09-27.
What conditions does trial NCT06066333 study?
This clinical trial studies the following conditions: Adrenocortical Carcinoma, ACC, Metastatic Adrenocortical Carcinoma.
What interventions are being tested in trial NCT06066333?
The interventions under investigation include: Pembrolizumab (DRUG), Ablative Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT06066333?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066333 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenocortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
-
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
ACTIVE NOT RECRUITING
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.